Diabetes Drug Reduces Heart Failure, Cardiovascular Death Risk
Patients with type 2 diabetes at high risk for cardiovascular disease who received empagliflozin had significantly lower rates of the composite cardiac vascular outcome and death from any cause.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.